MA68842B1 - Procédé de conjugaison de cys-mabs - Google Patents

Procédé de conjugaison de cys-mabs

Info

Publication number
MA68842B1
MA68842B1 MA68842A MA68842A MA68842B1 MA 68842 B1 MA68842 B1 MA 68842B1 MA 68842 A MA68842 A MA 68842A MA 68842 A MA68842 A MA 68842A MA 68842 B1 MA68842 B1 MA 68842B1
Authority
MA
Morocco
Prior art keywords
mabs
cys
conjugation process
present
capping
Prior art date
Application number
MA68842A
Other languages
English (en)
Inventor
Dante ROMANINI
James R. Falsey
Bradley J. Herberich
Michal ACHMATOWICZ
Oliver R. THIEL
Original Assignee
Amgen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=63371775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA68842(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc. filed Critical Amgen Inc.
Publication of MA68842B1 publication Critical patent/MA68842B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un procédé de coiffage, de réduction et d'oxydation de cys-mAbs permettant de fournir un matériau homogène destiné à des réactions de conjugaison ultérieures. Le présent procédé met en évidence des façons fiables de fabrication de conjugués d'anticorps modifiés par cystéine qui offrent un rendement élevé et une qualité constante de produit.
MA68842A 2017-08-04 2018-08-03 Procédé de conjugaison de cys-mabs MA68842B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762541522P 2017-08-04 2017-08-04
EP18759787.7A EP3661562B1 (fr) 2017-08-04 2018-08-03 Procédé de conjugaison de cys-mabs
PCT/US2018/045212 WO2019028382A1 (fr) 2017-08-04 2018-08-03 Procédé de conjugaison de cys-mabs

Publications (1)

Publication Number Publication Date
MA68842B1 true MA68842B1 (fr) 2025-01-31

Family

ID=63371775

Family Applications (1)

Application Number Title Priority Date Filing Date
MA68842A MA68842B1 (fr) 2017-08-04 2018-08-03 Procédé de conjugaison de cys-mabs

Country Status (19)

Country Link
US (2) US12594342B2 (fr)
EP (2) EP3661562B1 (fr)
JP (2) JP7504025B2 (fr)
AU (1) AU2018309090B2 (fr)
CA (1) CA3071852A1 (fr)
DK (1) DK3661562T3 (fr)
ES (1) ES2997332T3 (fr)
FI (1) FI3661562T3 (fr)
HR (1) HRP20241422T1 (fr)
HU (1) HUE069142T2 (fr)
LT (1) LT3661562T (fr)
MA (1) MA68842B1 (fr)
MX (2) MX2020001327A (fr)
PL (1) PL3661562T3 (fr)
PT (1) PT3661562T (fr)
RS (1) RS66295B1 (fr)
SI (1) SI3661562T1 (fr)
SM (1) SMT202400503T1 (fr)
WO (1) WO2019028382A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
EP4480537A3 (fr) 2017-01-17 2025-03-12 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs
TW202400244A (zh) * 2022-04-15 2024-01-01 美商瓦利托爾有限公司 經純化之多價蛋白質玻尿酸聚合物結合物
EP4577552A4 (fr) * 2022-08-22 2026-02-25 Suzhou Bioreinno Biotechnology Ltd Company Nouveau réducteur thiol, procédé et son utilisation
KR20260052949A (ko) * 2023-08-11 2026-04-20 암젠 인크 고체상 항체 접합 방법
CN122094712A (zh) * 2023-10-31 2026-05-26 山东博安生物技术股份有限公司 Gipr阻断型抗体及其抗体偶联物
CN122249239A (zh) * 2024-02-08 2026-06-19 苏州佰睿壹生物技术有限公司 抗体、抗体-药物偶联物及其制备方法
US20250276080A1 (en) * 2024-02-29 2025-09-04 Amgen Inc. Glucagon receptor agonists and conjugates to glucose-dependent insulinotropic polypeptide antagonists

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0281604B1 (fr) 1986-09-02 1993-03-31 Enzon Labs Inc. Molecules de liaison de chaines de polypeptide simples
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (fr) 1988-10-31 1990-05-17 Immunex Corporation Recepteurs d'interleukine-4
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690935A3 (fr) 1990-01-12 2008-07-30 Abgenix, Inc. Génération d'anticorps xenogéniques
WO1991018982A1 (fr) 1990-06-05 1991-12-12 Immunex Corporation Recepteurs de l'interleukine-1 de type ii
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
JPH06508035A (ja) 1991-06-14 1994-09-14 ディーエヌエックス　コーポレーション トランスジェニックブタにおけるヒトヘモグロビンの生産
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US6342225B1 (en) 1993-08-13 2002-01-29 Deutshces Wollforschungsinstitut Pharmaceutical active conjugates
CA2169298A1 (fr) 1993-09-10 1995-03-16 Martin Chalfie Utilisations d'une proteine fluorescente verte
WO1995021191A1 (fr) 1994-02-04 1995-08-10 William Ward Indicateur bioluminescent fonde sur l'expression d'un gene codant pour une proteine modifiee a fluorescence verte
CA2184002A1 (fr) 1994-02-23 1995-08-31 Jeffrey M. Blaney Procede et compositions permettant de prolonger la demi-vie serique d'agents a activite pharmacologique
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
CA2219361C (fr) 1995-04-27 2012-02-28 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
EP1972194A1 (fr) 1996-12-03 2008-09-24 Amgen Fremont Inc. Mammifères transgéniques disposant d'un loci ig comprenant plusieurs régions vh et vk et anticorps produits à partir de ceux-ci
ATE290205T1 (de) 1996-12-12 2005-03-15 Prolume Ltd Vorrichtung und verfahren zum nachweis und identifizieren von infektiösen wirkstoffen
CA2196496A1 (fr) 1997-01-31 1998-07-31 Stephen William Watson Michnick Epreuve de complementation de fragments de proteines pour la detection d'interactions entre proteines
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU765703B2 (en) 1998-03-27 2003-09-25 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
US20050054051A1 (en) 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US7837980B2 (en) * 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
US8633300B2 (en) * 2005-06-17 2014-01-21 Novo Nordisk Healthcare Ag Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
WO2006134174A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Composes fviia dimeres et multimeres
PE20090245A1 (es) * 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
PE20140625A1 (es) * 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
BRPI1015234A2 (en) * 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
CN103269720A (zh) 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
EP3079722B1 (fr) * 2013-12-13 2021-03-24 Novo Nordisk Health Care AG Procédé pour la conjugaison de protéines thioéther
MX2016010295A (es) * 2014-02-11 2016-10-17 Seattle Genetics Inc Reduccion selectiva de proteinas.
JP2017531620A (ja) * 2014-09-12 2017-10-26 ジェネンテック， インコーポレイテッド システイン操作抗体及びコンジュゲート
GB201419185D0 (en) 2014-10-28 2014-12-10 Adc Biotechnology Ltd Method of synthesising ADCs using affinity resin
AR103172A1 (es) 2014-12-22 2017-04-19 Novartis Ag Reducción selectiva de residuos de cisteina en anticuerpos il-17
CA2938333A1 (fr) * 2015-08-12 2017-02-12 Pfizer Inc. Anticorps a cysteines reticules et non reticules et leurs utilisations dans la combinaison anticorps-medicament
WO2017055582A1 (fr) * 2015-10-01 2017-04-06 Novo Nordisk A/S Conjugués de protéines
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
AU2017218615B2 (en) * 2016-02-12 2022-02-10 Byondis B.V. Selective reduction of cysteine-engineered antibodies
UY37376A (es) * 2016-08-26 2018-03-23 Amgen Inc Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso
EP4480537A3 (fr) * 2017-01-17 2025-03-12 Amgen Inc. Procédé de traitement ou d'amélioration de troubles métaboliques à l'aide d'agonistes du récepteur glp-1 conjugués à des antagonistes du récepteur du peptide inhibiteur gastrique (gipr)
MA68842B1 (fr) 2017-08-04 2025-01-31 Amgen Inc. Procédé de conjugaison de cys-mabs

Also Published As

Publication number Publication date
EP4464719A3 (fr) 2025-03-05
JP2024095687A (ja) 2024-07-10
MX2020001327A (es) 2020-03-20
SMT202400503T1 (it) 2025-01-14
EP3661562A1 (fr) 2020-06-10
JP2020529986A (ja) 2020-10-15
JP7877376B2 (ja) 2026-06-22
HUE069142T2 (hu) 2025-02-28
PL3661562T3 (pl) 2025-02-24
AU2018309090B2 (en) 2023-03-30
MX2025000220A (es) 2025-02-10
US20260034235A1 (en) 2026-02-05
EP4464719A2 (fr) 2024-11-20
AU2018309090A1 (en) 2020-02-20
LT3661562T (lt) 2024-10-25
SI3661562T1 (sl) 2025-01-31
WO2019028382A1 (fr) 2019-02-07
EP3661562B1 (fr) 2024-10-02
ES2997332T3 (en) 2025-02-17
US20210346513A1 (en) 2021-11-11
RS66295B1 (sr) 2025-01-31
FI3661562T3 (fi) 2024-12-09
HRP20241422T1 (hr) 2025-01-03
JP7504025B2 (ja) 2024-06-21
PT3661562T (pt) 2024-12-13
CA3071852A1 (fr) 2019-02-07
US12594342B2 (en) 2026-04-07
DK3661562T3 (da) 2024-12-16

Similar Documents

Publication Publication Date Title
MX2020001327A (es) Metodo de conjugacion de cys-acm.
EA201650081A3 (ru) 3d печатывающее устройство для изготовления объмного продукта
MX2024006675A (es) Anticuerpos monoclonales del receptor del factor de crecimiento 1 tipo insulina (igf-1r) y usos de los mismos.
MA49034B1 (fr) Anticorps anti-lag3
MX2019005438A (es) Dosificacion para tratamiento con anticuerpos bispecificos anti-cd20 / anti-cd3.
MX2018009493A (es) Uso combinado de al menos una endoproteasa y al menos una exoproteasa en un proceso simultaneo de sacarificacion y fermentacion (ssf) para mejorar la produccion de etanol.
MA40513A (fr) Conjugués médicament-anticorps anti-cdh6
SA520411849B1 (ar) أجسام مضادة ومتقارنات جسم مضاد مع عقار نوعية من أجل cd123 واستخداماتها
MY191384A (en) Method and device for producing planar modifications in solid bodies
SG11201901903TA (en) Method for producing lignocellulose materials
MX2021014178A (es) Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
MX2023013995A (es) Conjugados de anticuerpo y antraciclina.
MX2018015272A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
MX2020003497A (es) Metodo para generar anticuerpos multiespecificos a partir de anticuerpos monoespecificos.
MX2018015268A (es) Anticuerpos anti-cd98 y conjugados de anticuerpo y farmaco.
IL276211A (en) HU14.18K322A monoclonal antibody production process
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EP3980466A4 (fr) Procédés de production d'un anticorps anti-alpha4béta7
CO2020002156A2 (es) Produccion a gran escala de productos líquidos y solidos de trichoderma
MX2019011730A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
WO2018172758A3 (fr) Appareil et procédé chauffant
MX2016011579A (es) Emisor de haz de electrones.
MY189189A (en) Abstract method of spot welding
EP4400507A3 (fr) Méthode de chromatographie multidimensionnelle pour l'analyse de conjugués anticorps-médicament (cam)